Lorimer, C.F., Hanna, C. , Saran, F., Chalmers, A. and Brock, J. (2017) Challenges to treating older glioblastoma patients: the influence of clinical and tumour characteristics on survival outcomes. Clinical Oncology, 29(11), pp. 739-747. (doi: 10.1016/j.clon.2017.05.010) (PMID:28807361)
Full text not currently available from Enlighten.
Abstract
Aims: There is now evidence to support giving single-agent chemotherapy, radiotherapy or hypofractionated concurrent chemoradiotherapy to older patients with glioblastoma (GBM). However, the clinical basis on which treatment decisions are made is under-researched and not standardised. This retrospective, multicentre study assessed whether pre-morbid characteristics or tumour imaging features could predict for overall survival in a cohort of older patients with GBM. Materials and methods: Patients aged > 70 years, diagnosed with GBM at three neuro-oncology centres from 2010 to 2015 were retrospectively analysed. Demographic, clinical, radiological and treatment details were included in a multivariate model to examine for predictors of overall survival. Results: In total, 339 patients were included with a median overall survival of 3.8 months. One and 2 year overall survival rates were 13% and 4%, respectively. The median age at diagnosis was 75 years. Pre-treatment characteristics predicting for overall survival included Eastern Cooperative Oncology Group performance status over 0 (performance status 1, hazard ratio 1.66, P = 0.042; performance status 2, hazard ratio 1.78, P = 0.031; performance status 3, hazard ratio 2.20, P = 0.008; performance status 4, hazard ratio 2.40, P = 0.021), radiological evidence of mass effect (hazard ratio 1.31, P = 0.049), multifocal tumours (hazard ratio 3.419, P = 0.013), presenting with seizures (hazard ratio 0.63, P = 0.008) and tumours confined to the cerebral hemisphere (hazard ratio 0.59, P = 0.048). Subtotal resection decreased risk of death by 37% (P = 0.019) and total tumour resection by 44% (P = 0.019). Palliative radiotherapy decreased risk of death by 41% (P = 0.005), temozolomide alone by 60% (P = 0.004) and radical chemoradiotherapy by 81% (P < 0.001). Conclusion: Clinical presentation, performance status and imaging characteristics are independent prognostic indicators of overall survival in older GBM patients, irrespective of age or treatment received.
Item Type: | Articles |
---|---|
Additional Information: | We acknowledge support and funding from the Sussex Cancer Fund (grant reference 188170), the Beatson Cancer Charity (grant reference 15-16-086) and the Biomedical Research Council (grant reference A162). |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Hanna, Catherine and Chalmers, Professor Anthony |
Authors: | Lorimer, C.F., Hanna, C., Saran, F., Chalmers, A., and Brock, J. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Clinical Oncology |
Publisher: | Elsevier |
ISSN: | 0936-6555 |
ISSN (Online): | 1433-2981 |
Published Online: | 12 August 2017 |
University Staff: Request a correction | Enlighten Editors: Update this record